ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease
- Category: More News
- Published on Thursday, 19 November 2020 13:14
- Hits: 796
VICTORIA, Canada I November 19, 2020 I IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. IPA will generate novel bispecific antibody combinations using Genmab's proprietary DuoBody® platform and IPA's proprietary antibodies in the field of infectious disease. The development of IPA's proprietary antibodies into DuoBody constructs enables additional, novel formulations as the Company investigates a series of combinations in parallel.
"Partnering with Genmab aligns with IPA's mission to develop safe and effective therapies for patients, in this case, specifically pertaining to the growing demand in infectious disease," said Dr. Jennifer Bath, Chief Executive Officer of ImmunoPrecise Antibodies. "This agreement further complements our strategy to ensure that the full potential of our infectious disease programs is realized, which includes establishing productive partnerships to increase opportunities for ideal formulations with the highest safety and efficacy profiles."
The DuoBody technology is a proprietary platform of Genmab applied in the discovery and development of bispecific antibodies across several therapeutic areas including cancer, hemophilia, autoimmune, infectious, and central nervous system diseases. DuoBody technology has been successfully used in many Genmab internal or partnered investigational clinical therapies.
As a part of the partnership, Genmab and IPA will negotiate in good faith an agreement for the commercial use of resulting DuoBody products.
About ImmunoPrecise Antibodies Ltd.
SOURCE: ImmunoPrecise Antibodies